Talimogene laherparepvec (Imlygic)
Talimogene laherparepvec is an FDA-licensed reference biologic from Amgen Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2015
Reference approved
Reference product
Imlygic Talimogene laherparepvec
Amgen Inc.
- Approved
- Oct 27, 2015
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for Talimogene laherparepvec, in chronological order.
Reference approval
Approval date of the reference Talimogene laherparepvec product.
10 yr 9 mo ago
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
3 yr 8 mo ago
Frequently asked questions
Are there biosimilars approved for Talimogene laherparepvec (Imlygic)?
No 351(k) biosimilars or interchangeable biosimilars referencing Talimogene laherparepvec are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.